The Overlapping Biology of Sepsis and Cancer and Therapeutic Implications

• Published in: Biomedicines Vol. 13; no. 6; p. 1280
• Main Authors: Tripathi, Amit Kumar, Srivastava, Yogesh
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 23.05.2025; MDPI
• Subjects: Amino acids; Angiogenesis; Anti-inflammatory agents; Antimicrobial peptides; Apoptosis; Cancer; Cancer therapies; Cell activation; Cell death; Cell growth; Chemokines; CTLA-4 protein; Cytokine storm; Cytokines; Cytotoxicity; Development and progression; Diseases; Enzymes; Epigenetic inheritance; Epigenetics; Genomic instability; Glycolysis; Growth factors; Health aspects; Immune checkpoint inhibitors; Immune response; Immune system; Immunomodulation; Immunosuppression; Immunotherapy; Infections; Inflammation; Ipilimumab; Lymphocytes; Medical prognosis; Metabolism; Metastases; Metastasis; Microenvironments; Mortality; Oncology, Experimental; Paralysis; Pathophysiology; PD-1 protein; Recovery of function; Review; Risk factors; Sepsis; Storm damage; tumor microenvironment; Tumor necrosis factor-TNF; Tumor necrosis factor-α; Tumors; Warburg, Otto; immune response; inflammation; immunosuppression; cancer; cytokines; therapeutic targets; tumor microenvironment; sepsis
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines13061280

Sepsis and cancer, though distinct in their clinical manifestations, share profound pathophysiological overlaps that underscore their interconnectedness in disease progression and outcomes. Here we discuss the intricate biological mechanisms linking these two conditions, focusing on the roles of inflammation, immune dysregulation, and metabolic alterations. In sepsis, an uncontrolled immune response to infection leads to a cytokine storm, tissue damage, and immune paralysis, while cancer exploits chronic inflammation and immunosuppressive pathways to promote tumor growth and metastasis. Both conditions exhibit metabolic reprogramming, such as the Warburg effect in cancer and glycolysis-driven immune cell activation in sepsis, which fuels disease progression and complicates treatment. Sepsis can exacerbate cancer progression by inducing genomic instability, epigenetic modifications, and a pro-tumorigenic microenvironment, while cancer increases susceptibility to sepsis through immunosuppression and treatment-related complications. The shared pathways between sepsis and cancer present unique opportunities for therapeutic intervention, including anti-inflammatory agents, immune checkpoint inhibitors, and metabolic modulators. Anti-inflammatory therapies, such as IL-6 and TNF-α inhibitors, show promise in mitigating inflammation, while immune checkpoint inhibitors like anti-PD-1 and anti-CTLA-4 antibodies are being explored to restore immune function in sepsis and enhance antitumor immunity in cancer. Metabolic modulators, including glycolysis and glutaminolysis inhibitors, target the metabolic reprogramming common to both conditions, though their dual roles in normal and pathological processes necessitate careful consideration. Additionally, antimicrobial peptides (AMPs) represent a versatile therapeutic option with their dual antimicrobial and antitumor properties. In this review, we also highlight the critical need for integrated approaches to understanding and managing the complex interactions between sepsis and cancer. By bridging the gap between sepsis and cancer research, this work aims to inspire interdisciplinary collaboration and advance the development of targeted therapies that address the shared mechanisms driving these devastating diseases. Ultimately, these insights may pave the way for novel diagnostic tools and therapeutic strategies to improve outcomes for patients affected by both conditions.